HyperMabs is a biopharmaceutical company that designs and develops innovative monoclonal antibody-based therapeutics for life threatening diseases including COVID-19. We believe in connecting rigorous science with our innate sense of urgency to rapidly generate breakthrough therapies for patients in need of a better quality of life. Our highly qualified team of drug developers and company builders has a track record of advancing complex biologics from discovery through clinical trials.